Drug Profile
ABO 101
Alternative Names: AA9 NAGLU; AAV-NAGLU; ABO 101; ABX A; ABX-101; rAAV9-CMV-hNAGLU; rAAV9.CMV.hNAGLU; Sanfilippo syndrome type-B gene therapy; SC AAV9 NAGLULatest Information Update: 13 Jun 2022
Price :
$50
*
At a glance
- Originator Nationwide Children's Hospital
- Developer Abeona Therapeutics; Nationwide Children's Hospital
- Class Gene therapies
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mucopolysaccharidosis III
Most Recent Events
- 31 May 2022 Abeona Therapeutics terminates a phase I/II trial in Mucopolysaccharidosis III (In children, In infants, In adolescents, In adults, In the elderly) in USA, Germany and France (IV), as the company discontinued development activities due to a lack of drug supply and for business reasons unrelated to the product safety profile and signs of efficacy (NCT04655911)
- 07 Apr 2022 Abeona Therapeutics terminates the phase I/II Transpher B trial in Mucopolysaccharidosis III (In children, In neonates, In infants, In adolescents, In adults, In the elderly) in USA, France, Germany, Spain and the UK (IV) (NCT03315182)
- 01 Mar 2022 Discontinued - Phase-I/II for Mucopolysaccharidosis III (In adolescents, In children, In the elderly, In infants, In adults) in USA, Spain, France, Germany, United Kingdom (IV)